News Room

Grenoble, France, and Framingham, MA, 17 November, 2009 – CYTOO SA, a provider of innovative enabling technologies and products for high content cell analysis, announces today the opening of its wholly-owned U.S.-based subsidiary, CYTOO Inc., naming William T. Sharp president and CEO. Sharp also becomes a member of the Board of parent company Cytoo SA.
Sharp, who brings 30 years’ life science tools, diagnostics, and clinical product market experience to CYTOO, will have worldwide responsibilities for sales and marketing. He will also be charged with setting up co-distribution and partnership agreements with leading players in the cell based assays for the drug discovery market. Worldwide revenues for cell based assays were USD 1.7 billion in 2007, according to market data.
”Bill Sharp’s arrival as president and CEO of CYTOO, Inc. is the next step in the growth of our company and his commitment is further endorsement of the high potential of our technology and products,” says François Chatelain, co-CEO at CYTOO SA. “Bill’s track-record in strategic business development, leadership skills and in-depth knowledge of the industry means he will significantly reinforce our capacity to manage relations with US customers and provide us with valuable guidance as we grow.”
Prior to joining CYTOO, Sharp was president and CEO of ArunA Biomedical, a privately held stem cell technologies company, where he secured several measures, including licensing, co-development and distribution agreements, and
helped position the company for a series A-round. Before ArunA, he was chief commercial officer at BioProcessors Corporation, a venture-backed company offering proprietary micro-bioreactor technology. There, he played a leading role in raising USD 28 million in a series C financing round. Between 2004 – 2006, Sharp was vice president of business development with Cellomics, a market leader in high content screening technologies. While at Cellomics, he played a key leadership role in the USD 49 million sale of Cellomics to Fisher Scientific International. With a career spanning 30 years, his experience also includes senior leadership roles with Gentra Systems (acquired by Qiagen), Life Technologies (acquired by Invitrogen), Heraeus Instruments and Baxter Healthcare. Sharp earned M.S. and B.A. degrees from The Pennsylvania State
University.
“I look forward to working with my colleagues in France and our growing team here in the USA,” says Sharp. “CYTOO’s proprietary adhesive micropattern technology provides the foundation upon which we are developing and will commercialize a steady stream of innovative products targeted at applications in cell based assays, high content analysis and cell screening.”
“CYTOO’s products aim to help life science researchers take control of their cells by significantly decreasing cell variability and making cellular analysis more robust,” Sharp added. ”This unique capability, along with the team’s highly interactive approach to applications support, will enable CYTOO to form strong
bonds with customers and strategic partners as we work together to advance
their discovery efforts.”
In recent news, CYTOO announced the raising of EUR 3.2 million (USD 4.7 million) in a second round funding. The opening of this U.S. subsidiary and the hire of its CEO concludes a major step in the firm’s evolution and commercial development.

2009-11-19          download doc

Click on the Applications Tab in the menu bar to discover a few applications of micropattern technology.

The CYTOO technology and products offer a whole range of new possibilities for the scientist. While some applications have already been well established, others are developing.

Regularly updated, this page will give you a concise overview of the application fields.

2009-10-19

Grenoble, France, 28 September, 2009 – CYTOO SA, a provider of innovative enabling technologies and products for high content cell analysis, today announced the closing of a second funding round of USD 4.7M (EUR 3.2M). New investor, Auriga Partners, led the round. An existing investor Jacques Lewiner, co-founder and president of the supervisory board at CYTOO, also took part.
CYTOO will use the financing to grow its business internationally, expand the team and further its research and development in an area that is attracting increasing scientific and industrial interest.
“We are very pleased to support CYTOO as it enters a new phase in its development,” says Franck Lescure, partner at Auriga Partners. “With products already commercially available and a promising technology, CYTOO is exactly the type of early stage life sciences company with strong market potential that we look to finance.”
“Auriga Partners is a well-respected investor with an excellent reputation for working alongside early stage life science companies,” says François Chatelain, co-CEO at CYTOO. “Their participation in this round validates our business model and confirms the potential of our technology.”
CYTOO develops, manufactures and sells products that control internal cell organization, making analysis more reliable. Leveraging its exclusive ownership of an adhesive micropatterning technology, Cytoo focuses on applications in cell based assays, high content analysis and cell screening for the life science research market. Cytoo’s main product, CYTOOchipsTM, is aimed at the scientific research market. Future products under development will target pharmaceutical and biotechnology companies.
CYTOO holds an exclusive worldwide license from the Institut Curie and the CNRS (The French national scientific research center) for the adhesive micropattern patent portfolio, as well as license agreements with Harvard University (USA) and CEA, the largest government-funded technological research organization in France.
“CEA Investissement has supported CYTOO since its creation and we are delighted to have Auriga Partners join us at this exciting phase in the company’s development,” added Celia Hart, investment manager at CEA Investissement and member of the supervisory board at CYTOO.


2009-09-28          download doc

CYTOO has Marketing and Sales positions open in the USA

Check out our Careers page

http://www.cytoo.com/cytoo_career.php


2009-09-24           web site link

The CYTOOchamber™ is a 35mm footprint device specially designed and manufactured for our 2x2cm² square CYTOOchip™ format which enables you to do high resolution timelapse microscopy.

The CYTOOchamber uses a patented magnetic system (from Live Cell Instrument) for easy assembly. It is recommended for weak fluorescence signal observation.
The CYTOOchamber has the same footprint as standard 35mm culture dishes and therefore will fit into all 35mm microscope stage adaptors.


2009-09-09          download doc